Roya Attar
Optometrist · Jackson, MSNPI 1558788026
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), consulting fees and entertainment — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 21.1%. 2025 is the largest year on record at $6,187, 6.2 times the $1,002 reported in 2019. Among optometrist clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $166.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$4K
- Astellas Pharma US Inc$3K
- Bausch & Lomb Americas Inc.$2K
- Tarsus Pharmaceuticals, Inc.$2K
- Alcon$1K
- AbbVie$828
- plus $6K from 25 others
Across 2 payments — averaging $2429.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$5K
What the payments were for
- Consulting fees$9,29849%
- Speaking & faculty fees$2251%
- Food & beverage$9,35749%
- Entertainment$2551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 3 | $4,035 |
| Astellas Pharma US Inc | 8 | $3,187 |
| Bausch & Lomb Americas Inc. | 5 | $2,422 |
| Tarsus Pharmaceuticals, Inc. | 7 | $1,650 |
| Alcon | 11 | $1,102 |
| AbbVie(2 entities) | 10 | $828 |
| Glaukos Corporation | 9 | $799 |
| Coopervision Inc. | 8 | $664 |
| Johnson & Johnson Vision Care, Inc. | 6 | $546 |
| Heidelberg Engineering, Inc. | 3 | $508 |
| Sun Pharmaceutical Industries Inc. | 5 | $371 |
| Optos, Inc. | 4 | $348 |
| Genentech, Inc. | 4 | $332 |
| Harrow Eye, LLC | 2 | $271 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $271 |
| Dompe US, Inc. | 4 | $234 |
| Novartis | 3 | $201 |
| Aerie Pharmaceuticals, Inc. | 2 | $164 |
| Thea Pharma Inc. | 4 | $154 |
| Oyster Point Pharma, Inc. | 1 | $149 |
| Eyevance Pharmaceuticals LLC | 1 | $128 |
| Topcon Healthcare, Inc. | 1 | $120 |
| Kala Pharmaceuticals, Inc. | 2 | $100 |
| Astellas Pharma Global Development | 1 | $94 |
| Regeneron Healthcare Solutions, Inc. | 1 | $92 |
| Amgen | 1 | $84 |
| Notal Vision, Inc. | 1 | $75 |
| Neurotech Pharmaceuticals, Inc. | 1 | $68 |
| Janssen Global Services, LLC | 2 | $52 |
| Shire North American Group Inc | 1 | $46 |
| Carl Zeiss Meditec, Inc. | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$2,583
- Spectralis$508
- Acuvue$367
- XDEMVY$283
- CE-marked KXLA system$276
- TOTAL30$269
- MyDay Contact Lens$224
- PANORAMIC OPHTHALMOSCOPE$215
- OCT OPHTHALMOSCOPE$215
- TRIESENCE$149
- TYRVAYA$149
- RADIUS$144
- Precision7$132
- Zerviate$128
- Photrexa Viscous and Photrexa$126
- P200DTx$126
- P200T$126
- P200TE$126
- P200TxE$126
- INFUSE$125
How this compares
$19,135 in reported general payments places this provider in the 95th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 24 | $44,822 |
| RestasisCyclosporine | 15 | $13,967 |
| LumiganBimatoprost | 17 | $8,636 |
| Latanoprost | 203 | $1,431 |
| Fluorometholone | 12 | $1,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,650 | $44,82224 claims |
| AbbVieRestasis, Lumigan | $828 | $22,60332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Jackson
- Tina SoreyJackson$8K
- Christopher EvansJackson$4K
- Kregg BlyJackson$3K
- Kristopher MayColdwater$229K
- Alyssa MabrySenatobia$66K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
- Ramonica LewisClinton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.